NEW YORK (GenomeWeb) – Cytox said today that it has raised £2.6 million ($3.3 million) in new financing. The British genetics company will use the proceeds to support the roll out of its Alzheimer's disease testing service.

GM&C Life Sciences Fund — a Manchester, UK-based seed and early stage venture capital fund managed by Catapult Ventures — led the round as a new investor. Existing investors Perivoli Innovations, the Rainbow Seed Fund, the University of Oxford, and other private investors also contributed.